---

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

FORM 10-QSB

(Mark One)

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2008

[   ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF
THE EXCHANGE ACT

For the transition period from ___________________ to
___________________

Commission file number ___________________

PURE PHARMACEUTICALS CORPORATION(Exact name of small business issuer as specified in its
charter)

|NEVADA                                                               | 45-0476087                       
|-------------------------------------------------------------------- | ---------------------------------
|(State or other jurisdiction of incorporation or
      organization) | (IRS Employer Identification No.)

P.O. BOX 55, 1594 STONE MILL PARK, BELLONA, NY, 14415(Address of principal executive offices)

(315) 849-2822(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be
filed by Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [X]   No [   ]

Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).

Yes [X]   No [   ]

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's
classes of common equity, as of the latest practicable date: At March 31,
2008, there were 12,600,000 shares of the registrant's Common Stock outstanding.

Transitional Small Business Disclosure Format (Check one): Yes
[   ]   No [X]

Persons who are to respond to the collection of information
contained in this form are not required to respond unless the form displays
a currently valid OMB control number.

---

PART I  FINANCIAL INFORMATION

ITEM
1.              
FINANCIAL STATEMENTS

PURE PHARMACEUTICAL CORPORATION

(A Development Stage Company)

FINANCIAL STATEMENTS

MARCH 31, 2008

(Unaudited)

---

PURE PHARMACEUTICAL CORPORATION(A Development Stage Company)

BALANCE SHEETS

(Unaudited)

|                                                 |  | March 31, 2008 |   |  | September 30, 2007 |  
|------------------------------------------------ |  | -------------- | - |  | ------------------ | -
|                                                 |  | - $ -          |   |  | - $ -              |  
|ASSETS                                           |  |                |   |  |                    |  
|Current                                          |  |                |   |  |                    |  
|Cash                                             |  | 16,501         |   |  | 28,906             |  
|Inventory                                        |  | 5,130          |   |  | 5,130              |  
|                                                 |  | 21,631         |   |  | 34,036             |  
|                                                 |  |                |   |  |                    |  
|LIABILITIES                                      |  |                |   |  |                    |  
|Current                                          |  |                |   |  |                    |  
|Accounts payable and accrued liabilities         |  | 68,299         |   |  | 48,508             |  
|                                                 |  | 68,299         |   |  | 48,508             |  
|                                                 |  |                |   |  |                    |  
|STOCKHOLDERS DEFICIT                            |  |                |   |  |                    |  
|Authorized:                                      |  |                |   |  |                    |  
|100,000,000 common shares                        |  |                |   |  |                    |  
|With a par value of $0.001                       |  |                |   |  |                    |  
|Issued and Outstanding:                          |  |                |   |  |                    |  
|12,600,000 common shares                         |  |                |   |  |                    |  
|(September 30, 2006  12,600,000)                |  | 12,600         |   |  | 12,600             |  
|Additional paid up capital                       |  | 157,000        |   |  | 152,200            |  
|Accumulated comprehensive loss                   |  | 600            |   |  | 600                |  
|Deficit accumulated during the development stage |  | (216,868       | ) |  | (179,872           | )
|                                                 |  | (46,668        | ) |  | (14,472            | )
|                                                 |  | 21,631         |   |  | 34,036             |  

 See Accompanying Notes 

---

PURE PHARMACEUTICAL CORPORATION(A Development Stage Company)

STATEMENTS OF OPERATIONS

(Unaudited)

Period fromSeptember 24,2004Three months
    
    
    Three months
    
    
    Six months
    
    
    Six months
    
    
    (Inception) toended March
    
    
    ended March
    
    
    ended March
    
    
    ended March
    
    
    March 31,31, 2008
    
    
    31, 2007
    
    
    31, 2008
    
    
    31, 2007
    
    
    2008(Unaudited)
    
    
    (Unaudited)
    
    
    (Unaudited)
    
    
    (Unaudited)
    
    
    (Unaudited)-
      $ -
    
    
    -
      $ -
    
    
    -
      $ -
    
    
    -
      $ -
    
    
    -
      $ -Revenue
    
    -
    
    
    3,984
    
    
    -
    
    
    9,088
    
    
    12,088Cost of sales
    
    -
    
    
    3,187
    
    
    -
    
    
    7,270
    
    
    9,670-
    
    
    797
    
    
    -
    
    
    1,818
    
    
    2,418ExpensesFinancing fees
    
    -
    
    
    -
    
    
    -
    
    
    -
    
    
    5,600General andadministrative
    
    28,579
    
    
    3,613
    
    
    36,996
    
    
    9,053
    
    
    213,686Net loss
    
    28,579
    
    
    (2,816
    )
    
    36,996
    
    
    7,235
    
    
    (216,868
    )Basic and diluted lossper share
    
    (0.00
    )
    
    (0.00
    )
    
    (0.00
    )
    
    (0.00
    )Weighted averagenumber of commonshares outstanding
    
    12,600,000
    
    
    12,600,000
    
    
    12,600,000
    
    
    12,600,000


 See Accompanying Notes 

---

PURE PHARMACEUTICAL CORPORATION(A Development Stage Company)

STATEMENTS OF CASH FLOWS

(Unaudited)

|                                                 |  |             |   |  |             |   |  | Period from    |  
|------------------------------------------------ |  | ----------- | - |  | ----------- | - |  | -------------- | -
|                                                 |  |             |   |  |             |   |  | September 24,  |  
|                                                 |  | Six months  |   |  | Six months  |   |  | 2004           |  
|                                                 |  | ended March |   |  | ended March |   |  | (Inception) to |  
|                                                 |  | 31, 2008    |   |  | 31, 2007    |   |  | March 31,      |  
|                                                 |  | (Unaudited) |   |  | (Unaudited) |   |  | 2008           |  
|                                                 |  | -
      $ - |   |  | -
      $ - |   |  | -
      $ -    |  
|                                                 |  |             |   |  |             |   |  |                |  
|Cash Flows From Operating Activities             |  |             |   |  |             |   |  |                |  
|Net loss                                         |  | (36,996     | ) |  | (7,235      | ) |  | (216,868       | )
|Non-cash administrative expenses                 |  | 4,800       |   |  | 4,800       |   |  | 33,600         |  
|Net change in non-cash working capital balances: |  |             |   |  |             |   |  |                |  
|Inventory                                        |  | -           |   |  | 7,270       |   |  | (5,130         | )
|Accounts payable                                 |  | 19,791      |   |  | 23,150      |   |  | 68,299         |  
|Net cash used in operations                      |  | (12,405     | ) |  | (18,315     | ) |  | (120,099       | )
|                                                 |  |             |   |  |             |   |  |                |  
|Cash Flows From Financing Activities             |  |             |   |  |             |   |  |                |  
|Capital stock
      issued                       |  | -           |   |  | 2,000       |   |  | 136,000        |  
|Net cash provided by financing activities        |  | -           |   |  | 2,000       |   |  | 136,000        |  
|                                                 |  |             |   |  |             |   |  |                |  
|Effect of exchange rate changes                  |  | -           |   |  | 852         |   |  | 600            |  
|                                                 |  |             |   |  |             |   |  |                |  
|Increase (Decrease) In Cash                      |  | (12,405     | ) |  | (17,167     | ) |  | 16,501         |  
|                                                 |  |             |   |  |             |   |  |                |  
|Cash, beginning                                  |  | 28,906      |   |  | 54,124      |   |  | -              |  
|Cash, ending                                     |  | 16,501      |   |  | 36,957      |   |  | 16,501         |  
|                                                 |  |             |   |  |             |   |  |                |  
|Supplementary Cash Flow Information:             |  |             |   |  |             |   |  |                |  
|Cash paid for:                                   |  |             |   |  |             |   |  |                |  
|Interest                                         |  | -           |   |  | -           |   |  | -              |  
|Income taxes                                     |  | -           |   |  | -           |   |  | -              |  

- See Accompanying Notes -

---

PURE PHARMACEUTICAL CORPORATION(A Development Stage Company)

NOTE TO THE FINANCIAL STATEMENTS

MARCH 31, 2008 (Unaudited)

1.BASIS OF PRESENTATION

Unaudited Interim Consolidated Financial Statements

These unaudited interim financial statements may not include
all information and footnotes required by US GAAP for complete financial
statement disclosure. However, except as disclosed herein, there have been no
material changes in the information contained in the notes to the audited
financial statements for the year ended September 30, 2007, included in the
Companys Form 10-KSB and filed with the Securities and Exchange Commission.
These unaudited interim financial statements should be read in conjunction with
the audited financial statements included in the Form 10-KSB. In the opinion of
management, all adjustments considered necessary for fair presentation and
consisting solely of normal recurring adjustments have been made. Operating
results for the six months ended March 31, 2008 are not necessarily indicative
of the results that may be expected for the year ending September 30, 2008.

ITEM
2.              
MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Forward Looking Statements

In addition to historical information, the following discussion
and other parts of this document may contain forward-looking statements. These
statements relate to future events or our future financial performance. In some
cases, you can identify forward-looking statements by terminology such as "may,"
"will," "should," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential," or "continue," the negative of such terms or other
comparable terminology. These statements are only predictions. The events
described in forward looking statements we make in this Form 10-QSB may not
occur. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. We caution you that these
statements are not guarantees of future performance or events and are subject to
a number of uncertainties risks and other influences, many of which are beyond
our control that may influence the accuracy of the statements and the
projections upon which the statements are based. Moreover, neither we nor any
other person assume responsibility for the accuracy and completeness of the
forward-looking statements. Except as may be required by law, we undertake no
obligation to publicly update any of the forward-looking statements after the
date of this report to conform such statements to actual results or to changes
in our expectations.

Actual results could differ materially from those anticipated
by such forward-looking statements. The following discussion should be read in
conjunction with the financial statements as well as other financial information
appearing elsewhere in this document. Readers are also urged to carefully review
and consider the various disclosures made by us which attempt to advise
interested parties of the factors which affect our business.

---

Our Business

The Company was formed in order to seek business opportunities
in the area of expertise of the Company's principal stockholder, Mr. Roger
Gordon, being biological and/or medical products for animal use. The Company
principally operated in the field of generic animal health and nutrition
products, specifically medicated feed additives (MFAs). MFAs are used
preventively and therapeutically in animal feed to prevent disease and foster
growth in livestock. In North America, 90% of all feed to animals contain MFAs.
Our intended customers operate in the poultry, swine and cattle markets. The
Company has historically focused its efforts on generic MFAs, as they have come
off patent, therefore making them more economical to register with requisite
regulators in the United States and Canada, with a view to bringing the products
to market.

The Company continued to market a related-party owned MFA,
Oxytetracycline, and was in the exploratory phase of identifying generic MFAs
that it intended to test and register with regulatory authorities with a view to
being granted a DIN or similar authorization to market such MFAs in North
America (henceforth, the identification process). As market dynamics have
undergone significant systemic changes over the past three years with the
emergence of avian flu and the attendant fall in poultry consumption worldwide,
management has had to conduct the identification process with due deliberation.
Furthermore, with the prices of feed, particularly maize, at record high prices,
our intended customers have been hesitant to add to their expenses.

The Company's activities to date have been primarily
organizational in nature and as a result the Company must be considered to be in
its developmental stage. The Company relies solely on the efforts of its
management and director and has no employees, owns few business assets,
technology or real estate and since inception has been primarily involved in
developing its business plan, preliminarily identifying generic MFAs for
registration, and raising initial capital.

Results of Operations

Results of Operations for the Period ended March 31,
2008

We did not earn any revenues in the three months ended March
31, 2008. We incurred operating expenses in the amount of $28,579 for the three
months ended March 31, 2008. Our net loss for the three months ended March 31,
2008 was $28,579. As at March 31, 2008 we had cash of $16,501. The companys
losses stem from the payment of professional fees.

Sales and marketing of the companys Oxytetracyline and the
process of the company pursuing opportunities in the generic MFAs areas continue
to be very difficult. Due to an acute worldwide increase in the price of key
ingredients; corn and soybeans; the ability for producers to absorb upward
pricing pressure is severely challenged. Corn prices have surged three fold in
the last 24 months to its highest all time recorded price1.
Management and analysts believe the competition for corn, once viewed as a
commodity and now viewed as a matter of national security for countries, is here
to stay. The use of corn for the production of ethanol and the agricultural
polices of leading petroleum usage countries continue to exert price and demand
pressures on the market2.

Due to the prolonged high prices of inputs, an upward cycle
which has lasted for two years, and general conditions which are effecting the
business of the company; management has determined to refocus, assess, and
identify alternative business strategies.

_______________________________________________1
http://lfpress.ca/perl-bin/publish.cgi?x=articles&p=229715&s=shopping
2 http://www.financialpost.com/story.html?id=311350

---

Results of Operations from the Fiscal Year ended September
30, 2007

In the fiscal year ended September 30, 2007, we had net revenue
in the amount of $12,088, operating expenses in the amount of $64,886 and our
net loss was $62,468. As at September 30, 2007 we had cash of $28,906 and
working capital of $34,036.

As a result of its activities in late fiscal 2006, the Company
located suitable clients willing to purchase the MFA and was able to book its
first sale in the first quarter of fiscal 2007 for $5,104. During the second
quarter of fiscal 2007, the Company booked a sale in the amount of $3,984. In
the third quarter, the Company was unable to make any sales. In the fourth
quarter, the Company booked a sale of $3,000. Management believes that its
inability to generate greater sales is attributable to the high price of maize
which is one of the largest cost components of feed. Maize prices have increased
dramatically in the last 12 months from its historic averages. There are many
factors driving the price of maize higher, including its use as an emerging fuel
(ethanol). This significant jump in prices have forced upward "at the gate"
prices for poultry in cities such as Toronto where from the period of January to
June 2007, prices for poultry had increased 11.6% from $1.16 to $1.29/kilogram.
Management believes that until retail customers are willing to pay more, animal
producers are going to continue a cautious approach towards shouldering
additional "cost risk"

To broaden our distribution network, the Company set up a
website, www.purepharmacorp.com, to complement sales efforts.

Results of Operations for the Period ended September 30,
2006

We did not earn any revenue from the period from our inception
on September 24, 2004 to September 30, 2006. We incurred operating expenses in
the amount of $52,963 for the year ended September 30, 2006. These operating
expenses were comprised primarily of $38,322 for professional fees and $14,641
in office and general expenses. Our net loss for the year ended September 30,
2006 was $52,963. As at September 30, 2006 we had cash of $54,124 and working
capital of $35,692.

Since the acquisition of the license (CAS: 6153-64-6) to market
Oxytetracycline in Canada, in the third quarter of fiscal 2006 the Company was
able to secure manufacturing in the Far East with Jiangxi Pharmaceutical Factory
in China. After running tests, the factory demonstrated the efficacy of the
aforementioned MFA and the Company placed its first order and received
deliveries from its supply chain in the fourth quarter (July to September) of
fiscal 2006.

Results of Operations for Period Ending September 30, 2005
(as restated) from Inception

We did not earn any revenue from the period from our inception
on September 24, 2004 to September 30, 2005. We incurred operating expenses in
the amount of $64,441 for the year ended September 30, 2005. These operating
expenses were comprised primarily of $39,463 for professional fees and, $24,978
in office and general expenses. Our net loss for the year ended September 30,
2005 was $64,441. As at September 30, 2005, we had cash of $89,177 and working
capital of $72,600.

---

Liquidity and Capital Resources

Our cash reserves are not sufficient to meet our funding needs
beyond the next nine-month period. As a result, we will need to seek additional
funding in the near future. We currently do not have a specific plan for
obtaining such funding, however, we anticipate that any additional funding will
be in the form of equity financing from the sale of our common stock and/or
loans (interest or convertible). We currently do not have any arrangements in
place for any future equity financing. We may also seek to obtain short-term
loans from our directors, although no such arrangements have as yet been made.
There can be no assurance that we will able to raise sufficient funding from the
sale of our common stock or through director loans to meet our funding needs
after the next six months.

The Independent Auditor's Report to our audited financial
statements for the period ended September 30, 2007 indicated that there are a
number of factors that raise substantial doubt about our ability to continue as
a going concern. Such factors identified in the report include that we need to
generate profitable operations and are in need of obtaining adequate financing.
For these and other related reasons our auditors believe that there is
substantial doubt that we will be able to continue as a going concern.

Recent Developments

Sales have decreased year over year due to the increasing
prices of maize. As a result of the prolonged high prices of inputs and other
general conditions effecting the business of the Company, management has
determined, in the current quarter, to refocus, assess and identify alternative
business strategies.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on the
small business issuer's financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or
capital resources that is material to investors.

ITEM
3.              
CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures. The
Company's Management under the supervision and with the participation of the
Principal Executive Officer and the Principal Financial Officer are responsible
for establishing and maintaining "disclosure controls and procedures" (as
defined in the Exchange Act) for the Company. Based on their evaluation of the
Company's disclosure controls and procedures as of March 31, 2008, the Company's
Management has concluded that the Company's disclosure controls and procedures
were effective to ensure that the information required to be disclosed by the
Company under the Exchange Act was recorded, processed, summarized and reported
within the time periods specified in the Exchange Act and accumulated and
communicated to the Company's Management, including the Principal Executive
Officer and the Principal Financial Officer, to allow timely decisions regarding
required disclosure.

Changes in Internal Control over Financial Reporting.During the fiscal quarter ending March 31, 2008, there were no changes in
the Company's internal control over financial reporting during the period
covered by this report that have materially affected, or are reasonably likely
to materially affect, the Company's internal control over financial reporting.

Limitations on the Effectiveness of Controls.A control
system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are met.
Because of the inherent limitations in all control systems, no evaluation of
controls can provide

---

absolute assurance that all control issues, if any, within a
company have been detected. The Company's disclosure controls and procedures are
designed to provide reasonable assurance of achieving their objectives, and the
Principal Executive Officer and the Principal Financial Officer have concluded
that these controls and procedures are effective at the "reasonable assurance"
level.

ITEM 3A (T).    CONTROLS AND PROCEDURES

The Company's management is responsible for establishing and
maintaining adequate internal control over financial reporting. Our internal
control over financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted
accounting principles.

Our internal control over financial reporting includes those
policies and procedures that:

- Pertain to the maintenance of records that, in reasonable detail,
  accurately and fairly reflect the transactions and dispositions of the assets
  of the Company;
- Provide reasonable assurance that transactions are recorded as necessary to
  permit preparation of financial statements in accordance with generally
  accepted accounting principles, and that receipts and expenditures are being
  made only in accordance with authorizations of management and the director;
  and
- Provide reasonable assurance regarding prevention or timely detection of
  unauthorized acquisition, use or disposition of assets that could have a
  material effect on the financial statements.

As required by Rule 13a-15 and 15d-15 under the Securities and
Exchange Act of 1934, Management assessed the effectiveness of the Companys
internal control over financial reporting as of March 31, 2008. Based on this
assessment, the Company's management has concluded that the Company maintained
effective internal control over financial reporting as of March 31, 2008, the
end of the period covered by this quarterly report.

This quarterly report does not include an attestation report of
the company's registered public accounting firm regarding internal control over
financial reporting. Management's report was not subject to attestation by the
company's registered public accounting firm pursuant to temporary rules of the
Securities and Exchange Commission ("SEC") that permit the Company to provide
only management's report in this quarterly report.

Changes in Internal Control over Financial Reporting.Management has evaluated whether any changes in our internal control over
financial reporting that occurred during our last fiscal quarter have materially
effected, or reasonably likely to materially effect our internal control over
financial reporting. Based on the evaluation we conducted, management has
concluded that during the fiscal quarter ending March 31, 2008, there were no
changes in the Company's internal control over financial reporting during the
period covered by this report that have materially affected, or are reasonably
likely to materially affect, the Company's internal control over financial
reporting.

A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the
control system are met. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues, if any, within a company have been detected. The Company's
disclosure controls and procedures are designed to

---

provide reasonable assurance of achieving their objectives, and
the Principal Executive Officer and the Principal Financial Officer have
concluded that these controls and procedures are effective at the "reasonable
assurance" level.

PART II  OTHER INFORMATION

ITEM
1.              
LEGAL PROCEEDINGS.

We are not currently a party to any legal proceedings.

ITEM
2.              
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM
3.              
DEFAULTS UPON SENIOR SECURITIES

None.

ITEM
4.              
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters have been submitted to our security holders for a
vote, through the solicitation of proxies or otherwise, during the quarterly
period ended March 31, 2008.

ITEM
5.              
OTHER INFORMATION

None.

ITEM
6.              
EXHIBITS.

|31.1 | Certification
        of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley
        Act of 2002.
|---- | -----------------------------------------------------------------------------------------------------------------------
|     |                                                                                                                        
|31.2 | Certification
        of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley
        Act of 2002.
|     |                                                                                                                        
|32.1 | Certification
        of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley
        Act of 2002.
|     |                                                                                                                        
|32.2 | Certification
        of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley
        Act of 2002.

---

SIGNATURES

In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

|                   |  | PURE PHARMACEUTICALS CORPORATION                         
|------------------ |  | ---------------------------------------------------------
|                   |  | (Registrant)                                             
|                   |  |                                                          
|                   |  |                                                          
|Date: May 20, 2008 |  | By:/s/ Roger Gordon                                      
|                   |  | Roger Gordon                                             
|                   |  | President, Principal Executive Officer and
      Director
|                   |  |                                                          
|                   |  |                                                          
|                   |  |                                                          
|Date: May 20, 2008 |  | By:/s/ Charlie Lee                                       
|                   |  | Charlie Lee                                              
|                   |  | Secretary and Principal Accounting Officer               

---